The genetic basis of cancer is increasingly informing the development of personalized medicine, moving beyond traditional, broadly targeted therapies.  Advances in next-generation sequencing (NGS) have revolutionized our understanding of the complex mutational landscapes within individual tumors, revealing distinct driver mutations and enabling the identification of specific therapeutic vulnerabilities.  This has led to the emergence of targeted therapies, such as tyrosine kinase inhibitors (TKIs) for specific mutations in EGFR or ALK in lung cancer, demonstrating significant improvements in patient outcomes compared to conventional chemotherapy.  Furthermore, immunotherapy, harnessing the power of the patient's own immune system, has been significantly advanced by understanding tumor-specific neoantigens generated through genomic instability.  Immune checkpoint inhibitors, targeting proteins like PD-1 and CTLA-4, have shown remarkable efficacy in certain cancers, but their success is frequently contingent on the tumor's mutational burden and the patient's immune profile.  Ongoing research focuses on integrating genomic profiling with immunoprofiling to further refine patient selection for these therapies and predict response.  The ongoing development of liquid biopsies, allowing for minimally invasive monitoring of circulating tumor DNA (ctDNA), promises to further enhance early detection, treatment monitoring, and the identification of emerging resistance mutations, ultimately driving the precision and efficacy of personalized cancer care.